Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Novacyl is a global leader in the production of salicylic acid and its derivatives, most notably acetylsalicylic acid, commonly known as aspirin. The company operates as a major supplier of active pharmaceutical ingredients (APIs) for the pharmaceutical, cosmetic, and food industries worldwide. Originally a division of the Rhodia group, Novacyl was acquired by the Novacap Group, which subsequently rebranded as Seqens. With a dominant market share, the company maintains a robust manufacturing footprint across Europe, Asia, and the Americas. Its products are essential components in treatments for pain management, cardiovascular health, and dermatological conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Novacyl.